Neurogene Raises ~$135M in Equity Offering, Underwriters Exercise Full Option
NGNE has more than doubled off its 52-week low of $14.65 on elevated volume (3.8× avg).
Summary
Neurogene has successfully completed its equity offering, raising approximately $135 million in net proceeds, with underwriters exercising their full option to purchase additional shares. This significant capital raise, representing about 25% of the company's market capitalization, follows the highly positive long-term Phase 1/2 clinical data for its NGN-401 gene therapy announced on June 29th. The offering extends Neurogene's cash runway into 2029, providing crucial funding for operations. The full exercise of the underwriters' option signals strong market demand and investor confidence in the company's prospects.
At the time of this announcement, NGNE was trading at $31.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $535.4M. The 52-week trading range was $14.65 to $37.27. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.